Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David B Finlay

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Cellular Signalling|December 1, 2020
Biased agonism at the cannabinoid receptors - Evidence from synthetic cannabinoid receptor agonistsMonica Patel, David B Finlay, Michelle Glass
British Journal of Pharmacology|January 25, 2020
100 years of modelling ligand-receptor binding and response: A focus on GPCRsDavid B Finlay, Stephen B Duffull, Michelle Glass
Biochemical Pharmacology|April 11, 2024
GPCR kinase subtype requirements for arrestin-2 and -3 translocation to the cannabinoid CB<sub>1</sub> receptor and the consequences on G protein signallingJamie J Manning, David B Finlay, Michelle Glass
British Journal of Pharmacology|October 17, 2022
Cannabinoid 1 (CB<sub>1</sub> ) receptor arrestin subtype-selectivity and phosphorylation dependenceJamie J Manning, Gabriel Rawcliffe, David B Finlay, et al.
British Journal of Pharmacology|February 20, 2018
An evaluation of the operational model when applied to quantify functional selectivityXiao Zhu, David B Finlay, Michelle Glass, et al.
British Journal of Pharmacology|April 16, 2020
Evaluation of the profiles of CB<sub>1</sub> cannabinoid receptor signalling bias using joint kinetic modellingXiao Zhu, David B Finlay, Michelle Glass, et al.
Scientific Reports|February 24, 2019
An intact model for quantifying functional selectivityXiao Zhu, David B Finlay, Michelle Glass, et al.
British Journal of Pharmacology|April 5, 2019
Model-free and kinetic modelling approaches for characterising non-equilibrium pharmacological pathway activity: Internalisation of cannabinoid CB<sub>1</sub> receptorsXiao Zhu, David B Finlay, Michelle Glass, et al.
Peerj|March 29, 2016
GPR18 undergoes a high degree of constitutive trafficking but is unresponsive to N-Arachidonoyl GlycineDavid B Finlay, Wayne R Joseph, Natasha L Grimsey, et al.
Neuropharmacology|May 17, 2021
Pharmacological selection of cannabinoid receptor effectors: Signalling, allosteric modulation and biasJamie J Manning, Hayley M Green, Michelle Glass, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Cellular Signalling|December 1, 2020
Biased agonism at the cannabinoid receptors - Evidence from synthetic cannabinoid receptor agonistsMonica Patel, David B Finlay, Michelle Glass
British Journal of Pharmacology|January 25, 2020
100 years of modelling ligand-receptor binding and response: A focus on GPCRsDavid B Finlay, Stephen B Duffull, Michelle Glass
Biochemical Pharmacology|April 11, 2024
GPCR kinase subtype requirements for arrestin-2 and -3 translocation to the cannabinoid CB<sub>1</sub> receptor and the consequences on G protein signallingJamie J Manning, David B Finlay, Michelle Glass
British Journal of Pharmacology|October 17, 2022
Cannabinoid 1 (CB<sub>1</sub> ) receptor arrestin subtype-selectivity and phosphorylation dependenceJamie J Manning, Gabriel Rawcliffe, David B Finlay, et al.
British Journal of Pharmacology|February 20, 2018
An evaluation of the operational model when applied to quantify functional selectivityXiao Zhu, David B Finlay, Michelle Glass, et al.
British Journal of Pharmacology|April 16, 2020
Evaluation of the profiles of CB<sub>1</sub> cannabinoid receptor signalling bias using joint kinetic modellingXiao Zhu, David B Finlay, Michelle Glass, et al.
Scientific Reports|February 24, 2019
An intact model for quantifying functional selectivityXiao Zhu, David B Finlay, Michelle Glass, et al.
British Journal of Pharmacology|April 5, 2019
Model-free and kinetic modelling approaches for characterising non-equilibrium pharmacological pathway activity: Internalisation of cannabinoid CB<sub>1</sub> receptorsXiao Zhu, David B Finlay, Michelle Glass, et al.
Peerj|March 29, 2016
GPR18 undergoes a high degree of constitutive trafficking but is unresponsive to N-Arachidonoyl GlycineDavid B Finlay, Wayne R Joseph, Natasha L Grimsey, et al.
Neuropharmacology|May 17, 2021
Pharmacological selection of cannabinoid receptor effectors: Signalling, allosteric modulation and biasJamie J Manning, Hayley M Green, Michelle Glass, et al.
Pageof 4